Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486368 | 0.77 | PYGM (0.62) | PYGM | |
| SCHEMBL4696617 | 0.77 | PYGM (0.62) | PYGM | |
| SCHEMBL10351643 | 0.72 | PYGM (0.57) | PYGM | |
| SCHEMBL30162793 | 0.71 | PYGM (0.55) | PYGM | |
| SCHEMBL890639 | 0.70 | PYGM (0.52) | PYGM | |
| SCHEMBL7434274 | 0.69 | PYGM (0.51) | PYGM | |
| SCHEMBL1649443 | 0.68 | PYGM (0.52) | PYGM | |
| SCHEMBL20043145 | 0.64 | — | — | |
| SCHEMBL30622506 | 0.62 | PYGM (0.45) | PYGM | |
| SCHEMBL13657660 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538690-B1 | Arylquinoline substituted 1,4-dihydropyridine dicarboxylic derivatives, process for their preparation and their use as drugs | BAYER AG (DE) | 1994-09-28 | — | — | EP | claimed |
| US-5262429-A | CARDIOTONIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | claimed |
| EP-0172140-B1 | PROCESS FOR THE PREPARATION OF PYRIDINE-2,3-DICARBOXYLIC-ACID DERIVATIVES AND 1-AMINO-1,2,3,4-TETRAHYDRO-PYRIDINE-2,3-DICARBOXYLIC ACID DERIVATIVES AND 2,4-DIHYDROPYRIDINE-2,3-DICARBOXYLIC-ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1989-09-06 | — | — | EP | claimed |
| US-4754033-A | CLEAVAGE OF HYDRAZING GROUP, OXIDATION | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | claimed |
| JP-1038068-A | — | — | None | — | — | JP | disclosed |
| JP-7215938-A | — | — | None | — | — | JP | disclosed |
| JP-4234847-A | — | — | None | — | — | JP | disclosed |
| US-20080175800-A1 | USE OF SPECIFIC MENTHYL 3-OXOCARBOXYLIC ACID ESTERS AS PHYSIOLOGICALLY ACTIVE COOLING SUBSTANCES | SYMRISE GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-0588372-B1 | Process for preparing pyridine-2,3-dicarboxylic acid compounds | SUGAI CHEMICAL IND CO LTD (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6140401-A | COMPRISING SODIUM ALUMINOSILICATES, HYDROTALCITES AND CALCIUM-ALUMINIUM-HYDROXY-PHOSPHITES, AND AT LEAST ONE SOLID OR LIQUID ZINC SALT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2000-10-31 | — | — | US | disclosed |
| US-5475111-A | Process for the preparation of dihydropyridinecarboxylic acids | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-12-12 | — | — | US | disclosed |
| JP-H07215938-A | 1,4-DIHYDROPYRIDINEDICARBOXYLIC ACID MONOESTERS AND THEIR PRODUCTION | FUJISAWA PHARMACEUT CO LTD | 1995-08-15 | — | — | JP | disclosed |
| EP-0274379-A2 | Process for preparing pyridine-2,3-dicarboxylic acid compounds | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1988-07-13 | — | — | EP | disclosed |
| US-4754033-A | CLEAVAGE OF HYDRAZING GROUP, OXIDATION | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| US-4754033-A | CLEAVAGE OF HYDRAZING GROUP, OXIDATION | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| US-4754033-A | CLEAVAGE OF HYDRAZING GROUP, OXIDATION | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| US-4705786-A | Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-10 | — | — | US | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-3932646-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS | FARBENFABRIKEN BAYER AG (DT) | 1976-01-13 | — | — | US | disclosed |
| US-3932645-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS | FARBENFABRIKEN BAYER AG (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175800-A1 | USE OF SPECIFIC MENTHYL 3-OXOCARBOXYLIC ACID ESTERS AS PHYSIOLOGICALLY ACTIVE COOLING SUBSTANCES | ECI1, OTC, MDH2 | PYGM 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.